Array Digital Infrastructure Inc (AD) Stock News

Rosen Law Firm announces a securities class action lawsuit against XTI Aerospace, Inc. for investors who purchased securities between April 15, 2026 and August 17, 2026. The lawsuit alleges that senior executives engaged in undisclosed activities that required Board review, raising doubts about disclosure controls and the company's ability to file timely earnings reports. The firm is seeking a lead plaintiff by the October 27, 2026 deadline.

A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.

A class action lawsuit has been filed against The Simply Good Foods Company for allegedly making false statements regarding its OWYN acquisition. The lawsuit claims the company lost key personnel post-acquisition, faced product quality issues with a new pea protein supplier, engaged in excessive discounting to boost sales, and ultimately failed to achieve strategic goals, resulting in significant operational and financial problems for the OWYN segment.

Rosen Law Firm is urging UWM Holdings Corporation investors who purchased securities between March 9, 2026 and August 5, 2026 and suffered losses exceeding $100,000 to join a securities class action lawsuit before the October 13, 2026 lead plaintiff deadline. The lawsuit alleges that UWM Holdings made materially false statements regarding its hedging strategy for mortgage servicing rights, claiming the company deviated from its traditional non-hedging approach and over-hedged in anticipation of the Two Harbors transaction, creating excess hedging risk.

A securities class action lawsuit has been filed against HDFC Bank Limited for allegedly making materially false statements regarding its financial operations. The bank is accused of camouflaging payments as marketing spend to pay higher interest to a state firm to induce deposits, with activities allegedly approved by senior management and potentially violating regulations. Investors who purchased HDFC Bank securities between July 17, 2023 and May 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of October 13, 2026.

Rosen Law Firm is urging investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found was malfunctioning and dosing patients with dangerously high insulin levels. The firm claims thousands of complaints were filed with the FDA, contradicting defendants' assertions that issues were benign. The lead plaintiff deadline is November 3, 2026.

Rosen Law Firm has filed a class action lawsuit against Alphabet Inc. on behalf of investors who purchased securities between May 19, 2026 and July 16, 2026. The lawsuit alleges that Alphabet made materially false and misleading statements regarding the Gemini 3.5 Pro, claiming it delivered disappointing training results and would face significant launch delays. Investors who purchased during this period may be eligible for compensation. The deadline to serve as lead plaintiff is December 1, 2026.

HDFC Bank Limited faces a securities fraud class action lawsuit alleging that senior management concealed a covert scheme involving approximately Rs 45 crore ($4.7 million USD) in disguised payments to Maharashtra State Road Development Corporation to induce deposits. The scheme involved routing above-market interest rate differentials through the marketing department as fake sponsorship contributions, violating RBI regulations and internal anti-corruption policies. The fraud allegedly surfaced in March 2026 with the resignation of the Chairman citing ethical concerns, followed by a May 2026 investigative report exposing the scheme. Investors who purchased HDFC securities between July 17, 2023, and May 26, 2026, have until October 13, 2026, to apply as lead plaintiffs.

Hagens Berman announces a securities class action lawsuit against Aardvark Therapeutics for allegedly making materially false statements about ARD-101's safety. The company failed to disclose cardiac observations during trials, leading to a voluntary pause of the Phase 3 HERO trial in February 2026 (56% stock decline) and an FDA clinical hold in May 2026 (32.1% additional decline). Investors with substantial losses have until October 13, 2026, to become lead plaintiffs.

Beta Bionics (NASDAQ: BBNX) faces a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant shareholder losses during the class period of July 30, 2025 to February 24, 2026.

A securities class action lawsuit has been filed against The Simply Good Foods Company regarding materially false and misleading statements about its OWYN acquisition. The lawsuit alleges the company failed to disclose key managerial losses, product quality issues with the new pea protein supplier, ineffective promotional activities, and severe operational problems that undermined the acquisition's strategic goals. Investors who purchased SMPL stock between October 24, 2024 and April 8, 2026 may be eligible for compensation, with an October 13, 2026 deadline to serve as lead plaintiff.

Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies (PZZA, YSS, INV, XTIA) alleging materially false and misleading statements regarding business operations and prospects. Investors have until specified deadlines in late October and early November 2026 to file lead plaintiff motions.

Automatic Data Processing (ADP) has outperformed its industry with a 43.4% share price gain over six months. The company maintains a Zacks Rank #2 (Buy) rating with expected 5-6% revenue growth in fiscal 2027, driven by HCM technology, AI integration, and strategic acquisitions. Strong cash flow of $5.44B supports dividends, buybacks, and financial flexibility.

Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy.

The Security and Safety Services industry faces margin pressures from rising costs and labor expenses, but benefits from strong demand for security solutions. Four stocks highlighted are Allegion, ADT, Alarm.com Holdings, and Ituran Location and Control. The industry ranks #210 out of 247 Zacks industries and has underperformed the S&P 500 by 49.2% over the past year, though valuations remain attractive at 11.91X forward P/E versus the broader market's 19.99X.

Rosen Law Firm has filed a class action lawsuit against Duolingo, Inc. on behalf of investors who purchased Class A common stock between May 2, 2025 and February 26, 2026. The lawsuit alleges that Duolingo made materially false statements regarding Daily Active User growth rates, failed to disclose that increased user friction from ads and subscription upsells was negatively impacting DAU growth, and concealed that AI-generated content was degrading product quality and user experience. The deadline to serve as lead plaintiff is December 7, 2026.

Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026.

Rosen Law Firm has filed a class action lawsuit on behalf of Fluence Energy, Inc. (NASDAQ: FLNC) investors who purchased securities between November 24, 2025 and September 16, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding the company's ability to deliver its backlog and meet fiscal 2026 revenue guidance, citing incomplete manufacturing facilities and unresolved production problems. Investors who purchased during the class period may be entitled to compensation. The deadline to serve as lead plaintiff is November 30, 2026.

A securities class action lawsuit has been filed against DICK'S Sporting Goods, Inc. alleging that defendants made materially false and misleading statements regarding the company's cleanup efforts of Foot Locker's inventory, exposure to industry-wide excess inventory, and promotional pressures. The lawsuit claims these misstatements resulted in investors suffering damages. The lead plaintiff deadline is November 3, 2026.

Rosen Law Firm has filed securities class action lawsuits against Flotek Industries, FuelCell Energy, and Fluence Energy. The Flotek lawsuit alleges defendants made false statements regarding a Puerto Rico Electric Power Authority contract, claiming there were credible reasons to doubt the consortium's capacity to deliver promised revenues. Investors who purchased securities during specified class periods are encouraged to secure counsel before upcoming lead plaintiff deadlines.

Rosen Law Firm is notifying investors about securities class action lawsuits filed against GoDaddy Inc. and other companies. The GoDaddy lawsuit alleges the company made materially false statements about customer growth strategy and average order size, implementing promotions that contradicted public representations and led to decreased bookings. Investors who purchased stock during specified periods may be eligible for compensation, with an October 20, 2026 deadline to serve as lead plaintiff.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Innventure, Inc., where defendants allegedly made false statements about Accelsius Holdings' transformative deal with DarkNX and overstated revenue targets. The lead plaintiff deadline is October 27, 2026. Similar lawsuits are also being pursued against AST SpaceMobile, Inc. and GoDaddy Inc.

Rosen Law Firm has filed a class action lawsuit against Better Home & Finance Holding Company (BETR) on behalf of investors who purchased securities between March 13, 2026 and May 7, 2026. The lawsuit alleges that defendants made false and misleading statements regarding the company's conversion funnel and $1 billion monthly funded volume target, which were slowing due to macro factors. Investors who wish to serve as lead plaintiff must file by November 20, 2026.

MINISO Group (MNSO) gained 1.45% to $9.07, outperforming the broader market decline. The stock has declined 3.14% over the past month. Analysts expect upcoming earnings of $0.39 per share (up 11.43% YoY) and revenue of $1.01 billion (up 24.46% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 7.27, trading at a discount to its industry average of 13.88.

Robbins Geller announces a class action lawsuit against UWM Holdings Corporation for alleged securities violations. The lawsuit claims UWM made false statements about its hedging strategy for mortgage servicing rights in connection with the failed Two Harbors Investment Corp. merger. UWM reported a $603.2 million derivatives loss in Q2 2026, causing a 35% stock price decline. Investors with substantial losses can seek appointment as lead plaintiff by October 13, 2026.

Alps Alpine Co Ltd. (APELY) has received a Zacks Rank #2 (Buy) rating due to solid upward trends in earnings estimate revisions. The consensus estimate for the current quarter increased 39.22% over the past 30 days, while the full-year estimate rose 31.46%. The stock has gained 6.4% over the past four weeks and may have further upside potential based on improving analyst sentiment.

Yankuang Energy Group Company Limited Sponsored ADR (YZCAY) has been upgraded to Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The company is expected to earn $2.50 per share for fiscal year 2026, with analysts raising consensus estimates by 2.5% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation.

ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score.

Analog Devices (ADI) declined 2.49% in the latest session but maintains a Zacks Rank #1 Strong Buy rating. The semiconductor company is projected to report significant earnings growth of 69.91% YoY with revenue expected to rise 39.96%. Trading at a Forward P/E of 32.46, ADI trades at a discount to its industry average of 42.83, positioning it favorably for investors.